IDEAYA Biosciences IDYA 深 滬
等待開盤 12-12 09:30:00 美东时间
33.56
-0.080
-0.24%
華盛通- 最 高34.46
- 今 開33.98
- 成交量 58.56万股
- 最 低 33.331
- 昨 收 33.64
- 總市值 29.42亿
- 52周最高 37.08
- 市盈率 靜 --
- 換手率 0.67%
- 52周最低 13.45
- 委 比 -21.21%
- 總股本 8766.64万
- 歷史最高 47.735
- 量 比 0.52
- 振 幅 3.36%
- 歷史最低 2.95
- 每 手 1
- 風險率 4.81%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多GSK declares $0.4171/ADS or 16p/share dividend
GSK (GSK) declares $0.4171/ADS or 16p/share dividend, bringing total dividend declared to 64p/share in 2025. Forward yield 3.44% Payable Jan. 8; for shareholders of record Nov. 14; ex-div Nov. 14. See...
12-09 17:34
GlaxoSmithKline Ends Collaboration with IDEAYA Biosciences
IDEAYA Biosciences ( ($IDYA) ) has shared an update. On December 4, 2025, Glaxo...
12-06 05:49
On December 4, 2025 GSK Terminated Collaboration With IDEAYA Biosciences; GSK Will Transfer The Werner Helicase And Pol Theta Clinical Programs To The Co In Accordance With The Applicable Provisions Of The Agreement; IDEAYA Biosciences Will Evaluate Its Strategic Options For These Two Programs In 2026, And The Update Does Not Change Its Expectation Of Cash Runway Into 2030
On December 4, 2025, GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) ("GSK") communicated to IDEAYA Biosciences, Inc. (the "Company") its election to terminate the Collaboration, Option and License Agreement, dated
12-06 05:26
港股异动 | 百奥赛图-B(02315)涨超3% 授权IDEAYA双抗ADC项目IDE034获FDA IND批准
百奥赛图-B(02315)涨超3%，截至发稿，涨2.84%，报31.86港元，成交1299.1万港元。 消息面上，据百奥赛图-B官微消息，12月5日，公司宣布...
12-05 14:46
百奥赛图-B(02315.HK)合作伙伴IDEAYA取得美国FDA对IDE034的IND批准
【财华社讯】百奥赛图-B(02315.HK)公布，其合作伙伴IDEAYA Biosciences, Inc.(Nasdaq:IDYA)(“IDEAYA”)，已获...
12-05 08:51
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
11-25 10:27
Truist Securities Initiates Coverage On IDEAYA Biosciences with Buy Rating, Announces Price Target of $59
Truist Securities analyst Gregory Renza initiates coverage on IDEAYA Biosciences (NASDAQ:IDYA) with a Buy rating and announces Price Target of $59.
11-25 01:57
美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
11-12 11:43
Mizuho Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $46
Mizuho analyst Graig Suvannavejh maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and raises the price target from $44 to $46.
11-11 22:03
IDEAYA Biosciences Q3 EPS $1.33 Beats $(0.47) Estimate, Sales $207.834M Beat $5.975M Estimate
IDEAYA Biosciences (NASDAQ:IDYA) reported quarterly earnings of $1.33 per share which beat the analyst consensus estimate of $(0.47) by 380.59 percent. This is a 321.67 percent increase over losses of $(0.60) per share
11-04 19:29
